Biosimilars and Bioanalytical Methods
Biosimilars and Bioanalytical Methods is a research topic within Immunology. Science Explorer counts 17k research works in it since 1950. 14.9% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the immunogenicity of biosimilar therapeutics, including the validation of bioanalytical methods for assessing immunogenicity, the impact of manufacturing changes on immunogenicity, and the clinical outcomes and safety of switching from reference biologics to biosimilars. The use of dried blood spots for bioanalysis and the regulatory considerations for biosimilars are also prominent topics within this cluster.
- Biosimilars
- Immunogenicity
- Bioanalytical Methods
- Therapeutic Proteins
- Dried Blood Spots
- Erythropoietin Antibodies
- Monoclonal Antibodies
- Regulatory Guidelines
- Biopharmaceuticals
- Clinical Outcomes
- Research works
- 17k fractional, since 1950
- In the world top 10%
- 2.5k per year above
- Top-10% rate
- 14.9% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +45% the tick is no change
Which countries lead Biosimilars and Bioanalytical Methods research?
By volume, the United States and China publish the most (1.2k and 328 works in 2022–2025).
By volume, 2022–2025
- 1 United States 1.2k works
- 2 China 328 works
- 3 India 271 works
- 4 United Kingdom 264 works
- 5 Germany 219 works
- 6 Spain 186 works
- 7 France 157 works
- 8 Italy 144 works
- 9 Japan 120 works
- 10 Canada 117 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Biosimilars and Bioanalytical Methods research?
By volume in 2022–2025, Pfizer (United States) publishes the most Biosimilars and Bioanalytical Methods research, followed by University of North Carolina at Chapel Hill and Roche (Switzerland).
By volume, 2022–2025
- 1 Pfizer (United States) United States 23 works
- 2 University of North Carolina at Chapel Hill United States 21 works
- 3 Roche (Switzerland) Switzerland 17 works
- 4 The University of Texas MD Anderson Cancer Center United States 15 works
- 5 Harvard University United States 15 works
- 6 AbbVie (United States) United States 14 works
- 7 KU Leuven Belgium 14 works
- 8 Eli Lilly (United States) United States 13 works
- 9 Merck & Co., Inc., Rahway, NJ, USA (United States) United States 13 works
- 10 Center for Drug Evaluation and Research United States 12 works
Who are the leading researchers in Biosimilars and Bioanalytical Methods?
The most-cited researchers publishing on Biosimilars and Bioanalytical Methods include Nelson Alvis‐Guzmán.
- 1 Nelson Alvis‐Guzmán 7.7k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Biosimilars and Bioanalytical Methods research done?
The largest centres of Biosimilars and Bioanalytical Methods research in 2022–2025 are London (United Kingdom), New York (United States), Beijing (China) and Paris (France). Among places with at least 20 works in it, it is an unusually large share of all research in Silver Spring and Basel.
Largest cities, 2022–2025
Where it is the local speciality
- Silver SpringUS · 26.0 works30×
- BaselCH · 28.6 works11×
Location quotient: how much more of its research is in Biosimilars and Bioanalytical Methods than the world average.
Where is the best place to study Biosimilars and Bioanalytical Methods?
Among universities, judged by research, Icahn School of Medicine at Mount Sinai, KU Leuven and Harvard University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Icahn School of Medicine at Mount Sinai United States | 49.6 | 20.3% | 5.4× | 11 | +365.7% |
| 2 | KU Leuven Belgium | 49.1 | 18.0% | 4.0× | 14 | +148.2% |
| 3 | Harvard University United States | 47.0 | 23.2% | 2.9× | 15 | +90.2% |
| 4 | Medical University of Vienna Austria | 40.8 | 11.9% | 8.3× | 10 | +35.8% |
| 5 | University of California, San Francisco United States | 39.4 | 16.7% | 4.5× | 12 | +113.5% |
| 6 | China Pharmaceutical University China | 33.3 | 10.8% | 10.8× | 9 | -39.2% |
| 7 | University College London United Kingdom | 32.2 | 21.1% | 1.6× | 9 | +91.8% |
| 8 | Johns Hopkins University United States | 29.9 | 14.7% | 2.2× | 10 | +150.9% |
| 9 | University of North Carolina at Chapel Hill United States | 29.4 | 5.3% | 3.1× | 21 | +66.5% |
| 10 | University of Pennsylvania United States | 28.4 | 14.7% | 2.7× | 10 | +111.8% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Biosimilars and Bioanalytical Methods research growing?
Output in 2018–2022 was 45% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Biosimilars and Bioanalytical Methods.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.